A Medical Device Daily
Fisher Scientific International (Hampton, New Hampshire) filed a statement with the Securities and Exchange Commission (SEC) for issuing up to $1 billion of debt and equity securities.
This statement replaces the existing shelf-registration of $750 million, filed Sept. 3, 2003 (Medical Device Daily, Sept. 4, 2003). The company said it has no immediate plans to offer or sell any of its securities.
No securities may be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
Fisher is a provider of products and services to the scientific community. It serves pharmaceutical and biotech companies; colleges and universities; medical research institutions; hospitals; reference, quality-control, process-control and R&D labs in various industries; as well as government agencies.
Vantage Oncology (El Segundo, California), an owner and operator of radiation oncology centers nationwide, has secured $22 million in third-round financing.
The company said it will use the Series C funding to continue acquiring, joint venturing and developing cancer treatment facilities.
All of the existing investors in Vantage – New Enterprise Associates (NEA), Conning Capital Partners (CCP), Versant Ventures and Salix Ventures – have invested in this third round of financing, which was co-led by NEA and CCP.
“This round of financing will allow Vantage to continue executing on our mission of providing patients with improved access to advanced radiation therapy treatments in convenient community settings,” said Leslie Botnick, MD, medical director of Vantage Oncology.